TY - JOUR T1 - Treat to target in PsA should focus on clinical measures. Response to: ‘DAPSA versus cDAPSA: do we need to use CRP?’ by Gonçalves <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e143 LP - e143 DO - 10.1136/annrheumdis-2019-215990 VL - 79 IS - 11 AU - Leonieke J J van Mens AU - Marleen G H van de Sande AU - Arno W R van Kuijk AU - Dominique Baeten AU - Laura C Coates Y1 - 2020/11/01 UR - http://ard.bmj.com/content/79/11/e143.abstract N2 - We read with great interest, the work of Goncalves et al 1 submitted in response to our article,2 comparing potential treatment targets for patients with psoriatic arthritis in real world data. Our study showed considerable overlap between these targets, whether or not they included a laboratory measure of inflammation such as a C reactive protein (CRP). We concluded that ‘Inclusion of laboratory markers seems unnecessary’.This Brazilian study also used data from a real-life clinic cohort rather than a randomised controlled trial setting but only compared the two versions of the disease activity in PsA (DAPSA), with or without … ER -